Blog

Tejas Patil: MET and NF2 Alterations Linked to Primary Resistance in ALK TKI Therapy

Tejas Patil/X

Apr 23, 2025, 07:40

Tejas Patil: MET and NF2 Alterations Linked to Primary Resistance in ALK TKI Therapy

Tejas Patil, Thoracic oncologist at University of Colorado Cancer Center, shared a post on X by Molecular Oncology

“Primary resistance is to ALK TKIs is a major clinical issue. Nearly 20% of pts in CROWN trial progressed within 6 months! This study in Molecular Oncology shows that MET and NF2 alterations may play a role in primary (early) ALK resistance.”

“MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.”

Authors: Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song

ALK resistance cancer CROWN trial Donghui Zhang Hairong Bao Jie Hu Jiebai Zhou Jingwen Liu molecular oncology Ning Ding non small cell lung cancer OncoDaily Oncology Tejas Patil Xiaobo Xu Yang Shao Yedan Chen Yijun Song Yong Zhang Yuanlin Song

Senate President Passes Away After Brave Battle with Cancer: Dominick J. Ruggerio

Where to Study to Become ASCO President: 2025 Institutional Rankings

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

Dr. Don Dizon and Dr. Nathan Pennell Reflect on the Evolution of the ASCO Educational Book